UPDATE: Hofseth BioCare issues $21 million in 'significantly oversubscribed' private placement, moving to main Oslo stock exchange

Bookbuilding process will end tomorrow.

Jon Olav Odegard, CFO at Norwegian biotechnology firm Hofseth BioCare. — Jon Olav Odegard, CFO at Norwegian biotechnology firm Hofseth BioCare.Photo: Anders Furuset

Demi Korban

Published 15 October 2020, 15:54Updated 16 October 2020, 06:33

biotech Hofseth Biocare Roger Hofseth Oslo Stock Exchange Norway